In WP1 several groups undertake a systematic approach to uncover the impact of mesenchymal stromal components, such as pancreatic stellate cells and myofibroblasts. Using global profiling strategies and newly developed in situ profiling, the impact of these stroma cells on tumour initiation and progression is studied analyzing alterations in both gene expression and epigenetic modifications. One step ahead, WP1 creates a mouse model which enables the consortium to target genes specifically in pancreatic stellate cells, thereby creating an essential tool to decipher the impact of stellate cells in pancreatic cancer progression in-vivo. For preclinical testing of new therapeutic agents targeting the tumour stroma, a 3D spheroid minitumour model will be used which allows to systematically screen new compounds for their impact on tumour stroma and tumour cell survival in the presence of stellate cells.
Fundación Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) – Francesco Real
Philipps-Universität Marburg, Germany (UNIMAR)
Ernst-Moritz-Arndt-Universität Greifswald, Germany (EMAU-G)
Karolinska Institute, Sweden (KI)
Axcentua Pharmaceuticals Ltd., Sweden (Axcentua)
Technische Universität München, Klinikum rechts der Isar, Germany (TUM-MED)
Cancer Research UK, United Kingdom (CR-UK)